Skip to main content
Clinical Trials/NCT01332188
NCT01332188
Completed
Phase 2

A Single Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Efficacy of Three Different Concentrations of Cetirizine (0.05%, 0.1%, and 0.24%) Ophthalmic Solution Versus Vehicle in the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model (CAC)

Aciex Therapeutics, Inc.1 site in 1 country101 target enrollmentApril 2011

Overview

Phase
Phase 2
Intervention
AC-170 0.05%
Conditions
Allergic Conjunctivitis
Sponsor
Aciex Therapeutics, Inc.
Enrollment
101
Locations
1
Primary Endpoint
Ocular Itching at Duration of Action (24 Hours Post-dose)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) Model.

Registry
clinicaltrials.gov
Start Date
April 2011
End Date
October 2011
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Positive bilateral conjunctival allergen challenge (CAC) reaction

Exclusion Criteria

  • Known contraindications or sensitivities to the study medication or its components.
  • Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.
  • Use of disallowed medications during the period indicated prior to the study enrollment or during the study.

Arms & Interventions

AC-170 0.05%

Intervention: AC-170 0.05%

AC-170 0.1%

Intervention: AC-170 0.1%

AC-170 0.24%

Intervention: AC-170 0.24%

AC-170 0%

Intervention: AC-170 0%

Outcomes

Primary Outcomes

Ocular Itching at Duration of Action (24 Hours Post-dose)

Time Frame: 3, 5, 7 minutes post-CAC

A treatment efficacy CAC was performed 24 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Ocular Itching at Onset of Action (15 Minutes Post-dose)

Time Frame: 3, 5, 7 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Conjunctival Redness at Duration of Action (16 Hours Post-dose)

Time Frame: 7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 16 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Conjunctival Redness at Duration of Action (24 Hours Post-dose)

Time Frame: 7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 24 hours after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Conjunctival Redness at Onset of Action (15 Minutes Post-dose)

Time Frame: 7, 15, 20 minutes post-CAC

A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.

Ocular Itching at Duration of Action (16 Hours Post-dose)

Time Frame: 3, 5, 7 minutes post-CAC

A treatment efficacy CAC was performed 16 hours after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.

Secondary Outcomes

  • Ciliary Redness at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Ciliary Redness at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Ciliary Redness at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Episcleral Redness at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Episcleral Redness at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Episcleral Redness at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Chemosis at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Chemosis at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Chemosis at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Eyelid Swelling at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Eyelid Swelling at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Eyelid Swelling at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Tearing at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Tearing at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Tearing at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Rhinorrhea at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Rhinorrhea at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Rhinorrhea at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Pruritus at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Pruritus at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Pruritus at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Ear or Palate Pruritus at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Ear or Palate Pruritus at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Congestion at Onset of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Congestion at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Congestion at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Composite Score at Duration of Action (16 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Composite Score at Duration of Action (24 Hours Post-dose)(7, 15, 20 minutes post-CAC)
  • Nasal Composite Score at Onset of Action (15 Minutes Post-dose)(7, 15, 20 minutes post-CAC)
  • Tolerability of Study Medication at Visit 3A(upon instillation, 1 minute and 2 minutes post instillation)

Study Sites (1)

Loading locations...

Similar Trials